LV12177B - Antiglikokortikoīdu dabas ārstnieciskais līdzeklis - Google Patents

Antiglikokortikoīdu dabas ārstnieciskais līdzeklis Download PDF

Info

Publication number
LV12177B
LV12177B LVP-98-126A LV980126A LV12177B LV 12177 B LV12177 B LV 12177B LV 980126 A LV980126 A LV 980126A LV 12177 B LV12177 B LV 12177B
Authority
LV
Latvia
Prior art keywords
hjih
φβρομοηοβ
derivative
hto
agent
Prior art date
Application number
LVP-98-126A
Other languages
English (en)
Latvian (lv)
Other versions
LV12177A (lv
Inventor
Sergei Dmitrievich Burlakov
Dmitry Dmitrievich Genkin
Kirill Gennadievich Surkov
Viktor Veniaminovich Tets
Original Assignee
Sergei Dmitrievich Burlakov
Dmitry Dmitrievich Genkin
Kirill Gennadievich Surkov
Viktor Veniaminovich Tets
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sergei Dmitrievich Burlakov, Dmitry Dmitrievich Genkin, Kirill Gennadievich Surkov, Viktor Veniaminovich Tets filed Critical Sergei Dmitrievich Burlakov
Publication of LV12177A publication Critical patent/LV12177A/xx
Publication of LV12177B publication Critical patent/LV12177B/lv

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Securing Of Glass Panes Or The Like (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
LVP-98-126A 1996-01-31 1998-05-28 Antiglikokortikoīdu dabas ārstnieciskais līdzeklis LV12177B (lv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU96101194/14A RU2125446C1 (ru) 1996-01-31 1996-01-31 Антиглюкокортикоидное лекарственное средство
PCT/RU1996/000028 WO1997027845A1 (fr) 1996-01-31 1996-02-01 Medicament a base d'anti-glucocorticoide

Publications (2)

Publication Number Publication Date
LV12177A LV12177A (lv) 1998-12-20
LV12177B true LV12177B (lv) 1999-06-20

Family

ID=20175968

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-98-126A LV12177B (lv) 1996-01-31 1998-05-28 Antiglikokortikoīdu dabas ārstnieciskais līdzeklis

Country Status (24)

Country Link
US (1) US5965623A (sl)
EP (1) EP0896819A4 (sl)
JP (1) JPH11504946A (sl)
KR (1) KR100347862B1 (sl)
CN (1) CN1213964A (sl)
AU (1) AU710479B2 (sl)
BG (1) BG102709A (sl)
BR (1) BR9612470A (sl)
CA (1) CA2244985A1 (sl)
CZ (1) CZ160598A3 (sl)
EE (1) EE9800209A (sl)
GE (1) GEP20001955B (sl)
HU (1) HUP9900504A2 (sl)
LT (1) LT4441B (sl)
LV (1) LV12177B (sl)
MD (1) MD1430B1 (sl)
MX (1) MX9806182A (sl)
NO (1) NO983508D0 (sl)
PL (1) PL187564B1 (sl)
RU (1) RU2125446C1 (sl)
SI (1) SI9620053A (sl)
SK (1) SK65598A3 (sl)
UA (1) UA48212C2 (sl)
WO (1) WO1997027845A1 (sl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001039766A2 (en) * 1999-12-01 2001-06-07 Alydar Pharmaceuticals Ltd. Screening invertebrate pheromones for therapeutic activity
US6548706B2 (en) * 1999-12-23 2003-04-15 Aerojet Fine Chemicals Llc Preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl) -p-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines
EP1409656A4 (en) * 2001-03-12 2005-01-12 Darley Pharmaceuticals Ltd SCREENING OF PHEROMONAL COMPOUNDS OF NON-STEROID AND NON-PEPTIDE INVERTEBRATE HAVING ACTIVITY MODULATING MITOGEN-ACTIVATED PROTEIN KINASE
US6806293B1 (en) 2001-03-12 2004-10-19 Darley Pharmaceuticals Ltd Use of pheromone compounds having MAP kinase modulating activity
WO2003092614A2 (en) * 2002-05-02 2003-11-13 Hickle Randall S Lipid removal from the body
US6752649B2 (en) * 2002-11-07 2004-06-22 Xentris, Llc Illuminated indicia power supply apparatus and method of manufacture
DE10335845B4 (de) * 2003-05-09 2006-08-31 Müller, Martina, Dr.med. Pheromone als Antikrebsmittel
US20110195501A1 (en) * 2008-08-06 2011-08-11 Pangu Gautam D Ultrasonically induced release from polymer vesicles

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US161926A (en) 1875-04-13 Improvement in ink-wells
US2900756A (en) * 1958-12-09 1959-08-25 Jacobson Martin Attractants for the gypsy moth
EP0149847A3 (en) * 1983-12-26 1989-11-08 Eisai Co., Ltd. Therapeutic and preventive agent containing dolichol
JPH0759504B2 (ja) * 1986-01-23 1995-06-28 エーザイ株式会社 ポリプレニルアルコ−ル含有注射剤
US5019569A (en) * 1986-11-03 1991-05-28 Ortho Pharmaceutical Corporation Reversal of glucocorticoid-induced skin atrophy
US4740627A (en) * 1987-05-21 1988-04-26 Phillips Petroleum Company Synthesis of E,Z-11-tetradecen-1-al
ATE80313T1 (de) 1988-02-29 1992-09-15 Pfizer Mittel zur erhoehung des transdermalen penetrationsflusses.
US5190978A (en) * 1989-09-29 1993-03-02 Dai-Ichi Kogyo Seiyaku Co. Ltd. Carcinostatic compositions and methods

Also Published As

Publication number Publication date
GEP20001955B (en) 2000-03-05
PL322596A1 (en) 1998-02-02
EP0896819A4 (en) 2001-11-07
UA48212C2 (uk) 2002-08-15
CN1213964A (zh) 1999-04-14
LT98054A (en) 1998-10-26
LV12177A (lv) 1998-12-20
CA2244985A1 (en) 1997-08-07
MX9806182A (es) 1998-10-31
WO1997027845A1 (fr) 1997-08-07
PL187564B1 (pl) 2004-08-31
BR9612470A (pt) 1999-07-13
CZ160598A3 (cs) 1998-08-12
HUP9900504A2 (en) 1999-09-28
AU710479B2 (en) 1999-09-23
AU4636396A (en) 1997-08-22
NO983508L (no) 1998-07-30
BG102709A (en) 1999-06-30
EE9800209A (et) 1998-12-15
SK65598A3 (en) 1998-09-09
MD1430B1 (ro) 2000-03-31
KR100347862B1 (ko) 2003-01-24
JPH11504946A (ja) 1999-05-11
US5965623A (en) 1999-10-12
EP0896819A1 (en) 1999-02-17
SI9620053A (sl) 1998-04-30
KR19990076946A (ko) 1999-10-25
NO983508D0 (no) 1998-07-30
LT4441B (lt) 1999-01-25
RU2125446C1 (ru) 1999-01-27

Similar Documents

Publication Publication Date Title
LV12177B (lv) Antiglikokortikoīdu dabas ārstnieciskais līdzeklis
CO4480100A1 (es) Compuestos de 1-fenil-2-dimetilaminometil-ciclohexan-1-ol-, y procedimiento de preparacion para dichos compuestos
KR960000230A (ko) 간담즙성 질병 치료제
RU98104253A (ru) Новые опиоидные пептиды
UY28527A1 (es) Formularios de aerosol destinadaa la inhalación, que contiene un agente anticolinergico
KR940014374A (ko) 6,7-변형 패클리탁셀
KR940703676A (ko) 알렌드로네이트를 사용한 치근막 질환의 치료방법(Treatment of periodontal disease with alendronate)
ES2178724T3 (es) Acidos arilsulfonamido hidroxamicos alfa-sustituidos como inhibidores de factor de necrosis tumoral alfa y de metaloproteinasas de matriz.
GT199700016A (es) Derivados de triazol utiles en terapia
KR950014073A (ko) 이소퀴놀린
ES2147924T3 (es) Composicion terapeutica que comprende un antigeno o un generador in vivo de un compuesto que comprende una secuencia de aminoacidos.
MX9302123A (es) Procedimiento para la preparacion de un derivado de bifenilo.
ES2222517T3 (es) Analogos de iludina utiles como agentes antitumorales.
Bedford et al. Synthesis of water-soluble prodrugs of the cytotoxic agent combretastatin A4
FI890930A0 (fi) Menetelmä ihon kautta tapahtuvaa virtausta lisäävän farmaseuttisen valmisteen valmistamiseksi
ES2181849T3 (es) Procedimiento para minimizar la perdida osea.
ES2145971T3 (es) Procedimiento de preparacion de un cetal derivado de esteroide.
KR920012110A (ko) 산화형 글루타티온 알킬 에스테르
JPH0227970B2 (sl)
WO1994002145A3 (en) 2-aryl-4-quinolones as antitumor compounds
DE2830079A1 (de) Neue prostaglandinderivate der delta 2,4-11-desoxy-pge-reihe
RU97102700A (ru) Органические соединения
GB2135885A (en) Pharmaceutical compositions containing selenium compounds having antineoplastic activity
JPH06508134A (ja) コレステロール低下トコフェロール類似体
McCormick et al. Enhancement of murine hepatocarcinogenesis by all-trans retinoic acid and two synthetic retinamides